Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with a pathogenesis that remains incompletely understood, resulting in limited treatment options. MCC950, a highly specific NLRP3 inflammasome inhibitor, effectively suppresses the activation of NLRP3, thus reducing the production o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332224001422 |
| _version_ | 1797291814498074624 |
|---|---|
| author | Xiaoxiao Wu Junhao Yang Juanjie Wu Xuyan Yang |
| author_facet | Xiaoxiao Wu Junhao Yang Juanjie Wu Xuyan Yang |
| author_sort | Xiaoxiao Wu |
| collection | DOAJ |
| description | Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with a pathogenesis that remains incompletely understood, resulting in limited treatment options. MCC950, a highly specific NLRP3 inflammasome inhibitor, effectively suppresses the activation of NLRP3, thus reducing the production of caspase-1, the pro-inflammatory cytokines IL-1β and IL-18. This review highlights the pivotal role of NLRP3 inflammasome activation pathways in the pathogenesis of SLE and discusses the potential therapeutic application of MCC950 in SLE. Notably, it comprehensively elucidates the mechanism of MCC950 targeting the NLRP3 pathway in SLE treatment, outlining its potential role in regulating autophagy and necroptosis. The insights gained contribute to a deeper understanding of the value of MCC950 in SLE therapy, serving as a robust foundation for further research and potential clinical applications. |
| first_indexed | 2024-03-07T19:42:15Z |
| format | Article |
| id | doaj.art-1fc05776fbf445cd82d482f6295bcdb8 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-07T19:42:15Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-1fc05776fbf445cd82d482f6295bcdb82024-02-29T05:17:56ZengElsevierBiomedicine & Pharmacotherapy0753-33222024-03-01172116261Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosusXiaoxiao Wu0Junhao Yang1Juanjie Wu2Xuyan Yang3Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, ChinaDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155North Nanjing Street, Heping District, Shenyang 110001, ChinaDepartment of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, ChinaDepartment of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, China; Corresponding author.Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with a pathogenesis that remains incompletely understood, resulting in limited treatment options. MCC950, a highly specific NLRP3 inflammasome inhibitor, effectively suppresses the activation of NLRP3, thus reducing the production of caspase-1, the pro-inflammatory cytokines IL-1β and IL-18. This review highlights the pivotal role of NLRP3 inflammasome activation pathways in the pathogenesis of SLE and discusses the potential therapeutic application of MCC950 in SLE. Notably, it comprehensively elucidates the mechanism of MCC950 targeting the NLRP3 pathway in SLE treatment, outlining its potential role in regulating autophagy and necroptosis. The insights gained contribute to a deeper understanding of the value of MCC950 in SLE therapy, serving as a robust foundation for further research and potential clinical applications.http://www.sciencedirect.com/science/article/pii/S0753332224001422MCC950Systemic lupus erythematosusNLRP3 inflammasomeTherapeutic mechanismAutoimmune disease |
| spellingShingle | Xiaoxiao Wu Junhao Yang Juanjie Wu Xuyan Yang Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus Biomedicine & Pharmacotherapy MCC950 Systemic lupus erythematosus NLRP3 inflammasome Therapeutic mechanism Autoimmune disease |
| title | Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus |
| title_full | Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus |
| title_fullStr | Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus |
| title_full_unstemmed | Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus |
| title_short | Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus |
| title_sort | therapeutic potential of mcc950 a specific inhibitor of nlrp3 inflammasome in systemic lupus erythematosus |
| topic | MCC950 Systemic lupus erythematosus NLRP3 inflammasome Therapeutic mechanism Autoimmune disease |
| url | http://www.sciencedirect.com/science/article/pii/S0753332224001422 |
| work_keys_str_mv | AT xiaoxiaowu therapeuticpotentialofmcc950aspecificinhibitorofnlrp3inflammasomeinsystemiclupuserythematosus AT junhaoyang therapeuticpotentialofmcc950aspecificinhibitorofnlrp3inflammasomeinsystemiclupuserythematosus AT juanjiewu therapeuticpotentialofmcc950aspecificinhibitorofnlrp3inflammasomeinsystemiclupuserythematosus AT xuyanyang therapeuticpotentialofmcc950aspecificinhibitorofnlrp3inflammasomeinsystemiclupuserythematosus |